Advanced intelligence and close loop control for Crystallisation of API s Activ...
Advanced intelligence and close loop control for Crystallisation of API s Active Pharmaceutical Ingredients
The project aims to address key challenges of the pharmaceutical industry related to the consistent supply of active pharmaceutical ingredients (APIs) which are formed through crystallisation processes. Over 80% of the worlds API’...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
ATRS Instrument
Real time analysis of tablet and capsule dosage during pharm...
71K€
Cerrado
CTQ2009-08312
DESARROLLO DE NUEVAS METODOLOGIAS ESPECTRALES PARA EL CONTRO...
134K€
Cerrado
CTQ2016-79696-P
DISEÑO, MONITORIZACION Y OPTIMIZACION DE PROCESOS FARMACEUTI...
80K€
Cerrado
LCxLCProt
Comprehensive two dimensional liquid chromatography for the...
89K€
Cerrado
IMPAX
Inline Instant Measurement for PhArma eXtrusion
3M€
Cerrado
Información proyecto SmartCrys
Duración del proyecto: 26 meses
Fecha Inicio: 2018-12-14
Fecha Fin: 2021-02-28
Líder del proyecto
INNOPHARMA LABS LIMITED
No se ha especificado una descripción o un objeto social para esta compañía.
TRL
4-5
Presupuesto del proyecto
2M€
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
The project aims to address key challenges of the pharmaceutical industry related to the consistent supply of active pharmaceutical ingredients (APIs) which are formed through crystallisation processes. Over 80% of the worlds API’s have crystallisation steps. The current method of determining process performance is a combination of off-line analysis of the quality attributes of the API crystals after the crystallisation process is complete. This methodology does not control the manufacturing process and leads to a variable quality product, variable yields and a large proportion of rework batches, costing the API industry in excess of €10B/year. SmartCrys is an integrated solution for API processing issues of (1) in-line PAT Analysers to measure the critical quality attributes of the crystals, (2) Manufacturing Intelligence to interpret the data and decide whether process adjustments are required, (3) Process Automation which enable the automatic adjustment of the process to take place and (4) Data Analytics which enable visibility of all process data in real-time. SmartCrys enables rapid process development and subsequently self-adjustment of crystallization processes in real time, targeting an addressable market for SmartCrys of €20B. Through engagement with its customer base (8 of the top 10 Pharma companies worldwide) and the regulators, Innopharma have identified a technological gap in in-line process control among API manufacturers. SmartCrys will consolidate Innopharma’s position as one of the world’s leaders in Advanced Analytical Technologies within the pharmaceutical sector, and provide an opportunity to increase company turnover from €8M to €23M over the next 5 years and to grow staff from 45 to 65. It will also contribute to the continued competitiveness of the European API crystallization sector and help retain thousands of high-tech API manufacturing jobs within Europe.